A phase-2, multicenter, randomized, double-blinded, placebo-controlled, parallel-group, efficacy and safety study of apremilast (CC10004) in subjects with moderate to severe atopic dermatitis

1% effort 6 subjects

Awarded By

  • Celgene Corp

Contributors

Amount

  • $60,384.00

Start/End

  • August 1, 2014 - 2017